In our study, we divided the CD38-positive CLL patients into two groups, the CD38+ group and the CD38++group, with the cut-off levels of 6.0–30.0% and >30.0%, respectively, of the CD38-positive cells within the circulating CD19+CD5+ lymphocytes. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.